According to the World Health Organization, the number of Alzheimer鈥檚 patients worldwide is expected to skyrocket from the 35.6 million individuals who lived with it in 2010 to 115.4 million by 2050. Currently, however, all efforts to cure or effectively treat the disease have failed. Experts believe one explanation for this lack of success could be that the window of opportunity for treating Alzheimer鈥檚 has already closed by the time its symptoms manifest.
Enter the research team led by Howard Federoff, MD, PhD, executive dean at Georgetown University School of Medicine in Washington, D.C. In cognitively healthy adults age 70 and older, Federoff鈥檚 team measured the levels of 10 lipids found in the blood to identify, with 90% accuracy, which study group participants would develop cognitive impairment over a 2鈥�3 year period. If this 10-lipid test is validated in larger studies, it could help researchers to develop treatments for Alzheimer鈥檚 that halt or slow the disease before it even begins. A blood test would also be easier to perform than current Alzheimer鈥檚 tests that use brain imaging or hard-to-collect cerebrospinal fluid, meaning that the Federoff team鈥檚 test could be used for population-wide Alzheimer鈥檚 screening. Amrita Cheema, PhD, one of the main investigators on Federoff鈥檚 team, will give an in-depth lecture on the test鈥檚 significance, the science behind it, and the research techniques used to develop it in the July 28 AACC session, 鈥淟ipidomics: A Powerful Approach to Identify Pre-clinical Memory Impairment in Older Adults.鈥� Cheema is an associate professor and co-director of the Proteomics and Metabolomics Shared Resource at Georgetown University.
鈥淭his discovery is a potentially enormous breakthrough in the fight against Alzheimer鈥檚,鈥� said AACC CEO Janet B. Kreizman. 鈥淚f research aimed at a cure for Alzheimer鈥檚 is to move forward, it is crucial that Alzheimer鈥檚 clinical trials find a way to recruit patients who are still asymptomatic, since they are the ones most likely to respond to treatment. The Federoff team鈥檚 test could be the answer to this problem, and it also demonstrates how laboratory medicine helps patients achieve better health鈥攂y not only ensuring that patients receive timely and appropriate treatment, but also by enabling researchers to develop effective treatments in the first place.鈥�
________________________________________Session InformationAACC annual meeting registration is free for members of the media. Reporters can register online here:
Lipidomics: A Powerful Approach to Identify Pre-clinical Memory Impairment in Older AdultsMonday, July 28 10:30鈥�11:30 a.m.McCormick Place Room S105BCChicago
About the 2014 AACC Annual Meeting & Clinical Lab ExpoAACC's Annual Meeting offers 5 days packed with opportunities to learn about exciting science from July 27鈥�31. Plenary sessions feature expert presentations on how mobile technology and the internet are revolutionizing healthcare, the importance of newborn screening, big data, the biologic basis of obesity, and the latest advances that could lead to a cure for HIV.
At the AACC Clinical Lab Expo, more than 700 exhibitors will fill the show floor of Chicago鈥檚 convention center, McCormick Place, with displays of the latest diagnostic technology, including but not limited to automation, information systems, point-of-care, and biotech.
About AACCDedicated to achieving better health through laboratory medicine, AACC brings together more than 50,000 clinical laboratory professionals, physicians, research scientists, and business leaders from around the world focused on clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking laboratory science. Since 1948, AACC has worked to advance the common interests of the field, providing programs that advance scientific collaboration, knowledge, expertise, and innovation. For more information, visit .
RSS